Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Actions

Share

.1989 Jul;39(7):782-5.

Action of beta-adrenoceptor blockers on liver function of rats

Affiliations
  • PMID:2571334

Action of beta-adrenoceptor blockers on liver function of rats

J Kulcsár-Gergely. Arzneimittelforschung.1989 Jul.

Abstract

Three nonselective beta-adrenoceptor blockers, propranolol, cloranolol and talinolol, were examined in male rats. The amount and function of polysubstrate monooxygenase, serum bilirubin and carbohydrate metabolism were investigated. Doses producing a 25% reduction in heart beat/min were given orally. The effect of a single dose was compared to that of a 12-day treatment period. Propranolol in a single dose did not influence hepatic parameters. The 12-day treatment reduced the amount of cytochrome P-450 (cP-450) and prolonged hexobarbital biotransformation time. Cloranolol decreased cP-450, prolonged hexobarbital anaesthesia and inhibited aminopyrine-N-demethylation (AND) even in a single dose. No further impairment occurred with continued treatment. A single dose of talinolol led to cP-450 loss and inhibited cP-450 dependent liver functions. This inhibition progressed with continued treatment. High bilirubin levels were measured. Both cloranolol and talinolol elicited an initial rapid hyperglycaemia with normal liver glycogen content. At the end of the treatment blood glucose and liver glycogen values were normal. The reversible hyperglycemic reaction shows the necessity of controlling glucose tolerance. When talinolol is administered liver function parameters should be checked in appropriate time intervals.

PubMed Disclaimer

Similar articles

See all similar articles

MeSH terms

Substances

Related information

LinkOut - more resources

Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp